Skip to content
AnalystLens

NBIX · Neurocrine Biosciences

289 filings

8-K

NBIX 8-K Current Reports

Neurocrine Biosciences - 289 current reports

Filing record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25
Showing 1-50 of 289 filings
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Nov 2, 2026)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported third-quarter 2026 financial results on November 2, 2026, with total revenues of $1,123 million, up 41% year-over-year from $795 million. INGREZZA net product sales were $801 million (up 17%), CRENESSITY net product sales were $211 million (up 115%), and VYKAT XR net product sales were $107 million. The company said net product sales exceeded $1 billion for the first time. GAAP net income was $207 million ($1.96 diluted EPS) versus $210 million ($2.04) a year earlier, while non-GAAP net income was $347 million ($3.29 diluted EPS) versus $222 million ($2.17). The company raised its full-year 2026 INGREZZA net product sales guidance to $2.90 to $2.925 billion from $2.825 to $2.875 billion. Updated full-year guidance also lowered GAAP SG&A to $1.540 to $1.560 billion from $1.575 to $1.600 billion, and raised IPR&D to $34 million from $23 million; GAAP R&D guidance was unchanged. Results reflect the May 2026 acquisition of Soleno Therapeutics, Inc., which added VYKAT XR and about $2.2 billion of related intellectual property. Cash, cash equivalents and marketable securities were approximately $790 million at September 30, 2026, compared with $2,543 million at December 31, 2025. Other developments include Phase 1 initiation for NBIP-'1968 (a GLP-1/GIP/glucagon triple agonist for obesity), a Phase 2 study of NBI-'567 for cognitive impairment in Alzheimer's disease, and the appointment of Eiry W. Roberts, M.D. as Chief Medical Officer. The company will host an R&D Day in New York on December 15, 2026. The filing furnishes the earnings release under Item 2.02, which is not deemed filed for purposes of Section 18 of the Exchange Act.

Nov 2, 2026
8-K
Leadership Changes

Neurocrine Biosciences 8-K Report, Executive Changes (Sep 28, 2026)

Neurocrine Biosciences, Inc. disclosed a leadership change in its executive team. Its Board of Directors appointed Eiry W. Roberts, M.D., as Chief Medical Officer, succeeding Sanjay Keswani, M.D., effective September 28, 2026. The filing states that Dr. Keswani and the Board mutually agreed that his service as Chief Medical Officer would terminate as of September 25, 2026. Dr. Keswani will be entitled to severance benefits under Section 4.1 of the Company's Executive Severance Plan, subject to the plan's terms. The Company will enter into an Amended and Restated Employment Agreement with Dr. Roberts, effective as of the transition date, which replaces his May 30, 2025 employment agreement, as amended on November 21, 2025. Under the new agreement, Dr. Roberts will receive an annual base salary of $825,000 and a target annual cash bonus equal to 60% of base pay for calendar year 2026. He will also receive equity grants under the 2025 Equity Incentive Plan with target grant values of approximately $625,000 in stock options, $250,000 in restricted stock units, and $375,000 in performance-vesting restricted stock units. The equity grants are scheduled to be made two business days after the Company files its first Form 10-Q following the transition date, provided he remains employed. Dr. Roberts' existing equity awards will remain outstanding and continue vesting under their terms. The summary in the filing is not the full agreement. The Company anticipates filing the complete Employment Agreement with its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026. The filing also includes standard forward-looking statement cautions.

Sep 28, 2026
8-K/A
Exhibits & Filings

Neurocrine Biosciences 8-K/A Report, Exhibit Filing (Jul 31, 2026)

Neurocrine Biosciences, Inc. filed this Amendment No. 1 on Form 8-K/A to amend its May 18, 2026 Current Report, which reported the completion of its merger with Soleno Therapeutics, Inc. The amendment adds Soleno's audited consolidated financial statements for the year ended December 31, 2025 (Exhibit 99.1), its unaudited interim condensed consolidated financial statements for the three months ended March 31, 2026 (Exhibit 99.2), and unaudited pro forma condensed combined statements of income for the six months ended June 30, 2026 and the year ended December 31, 2025 (Exhibit 99.3). The filing states that it does not update any other item or discuss developments after the original report's filing date. The acquisition, completed on May 18, 2026 at a price of $53.00 per Soleno share in cash, added VYKAT XR (diazoxide choline), described as a first-in-class therapy for hyperphagia in Prader-Willi syndrome. The pro forma statements, prepared under the acquisition method with Neurocrine as the accounting acquirer, show pro forma total revenues of $1,907.5 million and net income of $294.0 million for the six months ended June 30, 2026, and total revenues of $3,050.9 million and net income of $324.5 million for 2025. Diluted pro forma earnings per share are $2.83 and $3.17, respectively. The statements exclude synergies and cost savings, and the company describes the fair value estimates as preliminary, with the purchase accounting to be finalized within one year of the closing date. Financing was provided through a May 14, 2026 credit agreement for a five-year, $1.0 billion senior secured revolving credit facility. The company drew $600.0 million on May 18, 2026 at an initial rate of 4.896% (Term SOFR plus 1.25%) and had repaid the full amount as of June 30, 2026. The filing also reports an estimated $2,237.8 million fair value for the VYKAT XR intangible asset, with a 16-year useful life, and a $168.2 million inventory fair value step-up.

Jul 31, 2026
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Jul 30, 2026)

Neurocrine Biosciences, Inc. (NBIX) reported second-quarter 2026 total revenues of $959 million, up 39% year over year from $688 million. INGREZZA net product sales were $716 million (up 15%), CRENESSITY net product sales were $184 million (up 247% from $53 million), and VYKAT XR net product sales were $54 million, included from the May 18, 2026 closing of the Soleno Therapeutics acquisition. Unaudited pro forma total revenues including a full quarter of VYKAT XR were $998 million. GAAP net income was $144 million, or $1.39 per diluted share, compared with $108 million, or $1.06, a year earlier. Non-GAAP net income was $297 million, or $2.85 per diluted share, compared with $166 million, or $1.65. The company raised its full-year 2026 INGREZZA net product sales guidance to $2.825 billion to $2.875 billion, from $2.7 billion to $2.8 billion. It also raised GAAP R&D guidance to $1.275 billion to $1.325 billion and GAAP SG&A guidance to $1.575 billion to $1.600 billion, reflecting pipeline investment and commercial spending for the launches. The Soleno acquisition was completed in May 2026 at $53.00 per share in cash, a total equity value of $2.9 billion. Cash, cash equivalents and marketable securities totaled $482 million at June 30, 2026, down from $2,543 million at December 31, 2025. The company also entered a $1.0 billion senior secured revolving credit facility in May 2026, with the full $1.0 billion available at June 30, 2026. Management highlighted two Phase 3 readouts expected in 2027 for osavampator in major depressive disorder and direclidine in schizophrenia. The filing states that the press release is furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act.

Jul 30, 2026
8-K
Leadership ChangesShareholder Matters

Neurocrine Biosciences 8-K Report, Executive Changes (May 28, 2026)

Neurocrine Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on May 27, 2026, with 90,118,625 of 100,581,991 eligible shares (record date March 31, 2026) present in person or by proxy. Stockholders elected three Class III Directors to terms expiring at the 2029 Annual Meeting: Kevin C. Gorman, Ph.D. (76,228,063 votes for), Gary A. Lyons (75,278,705 votes for), and Johanna Mercier (74,671,942 votes for). Continuing directors are William H. Rastetter, Ph.D., George J. Morrow, Leslie V. Norwalk, and Christine A. Poon (Class I, term expiring 2027), and Kyle W. Gano, Ph.D., Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D. (Class II, term expiring 2028). Stockholders also approved, on an advisory basis, the compensation paid to the company's named executive officers (78,993,894 for, 5,669,155 against, 103,231 abstentions). They approved the amendment of the 2025 Equity Incentive Plan (the "Amended 2025 Plan") with 79,131,622 votes for and 5,568,926 against. A summary of the Amended 2025 Plan's material terms appears in the definitive proxy statement filed April 15, 2026, which is incorporated by reference. Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 83,880,185 votes for and 6,170,483 against. This filing reports routine annual meeting outcomes, with no material change to officers or directors disclosed.

May 28, 2026
8-K
Acquisitions & DispositionsMaterial AgreementsFinancial Events+2

Neurocrine Biosciences 8-K Report, Material Agreement (May 18, 2026)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) completed its acquisition of Soleno Therapeutics, Inc. on May 18, 2026, through a cash tender offer at $53.00 per share followed by a merger under Section 251(h) of the Delaware General Corporation Law, with Soleno becoming a direct, wholly owned subsidiary. As of the offer expiration at one minute after 11:59 p.m. Eastern time on May 15, 2026, 46,356,114 Soleno shares, representing approximately 88.9% of issued and outstanding shares, had been validly tendered, satisfying the minimum condition. The aggregate cash paid in the offer and merger was approximately $2.9 billion, plus fees and expenses, funded from Neurocrine's available cash on hand. Soleno's Soleno Options with exercise prices below the offer price, and Soleno RSU Awards, were cashed out, and Soleno's common stock is no longer listed on the Nasdaq Capital Market. The acquisition adds VYKAT XR (diazoxide choline) extended-release tablets, approved by the FDA on March 26, 2025, for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome, to Neurocrine's commercial portfolio alongside INGREZZA and CRENESSITY. Neurocrine describes the product as the first and only approved treatment for hyperphagia in Prader-Willi syndrome. The company also disclosed a new five-year, $1.0 billion senior secured revolving credit facility dated May 14, 2026, with JPMorgan Chase Bank, N.A. as administrative agent, under which it made an initial borrowing of $600.0 million on the closing date. The credit agreement includes a maximum total net leverage ratio of 3.75:1.00, which may increase to 4.25:1.00 for certain periods following material acquisitions, and a minimum consolidated interest coverage ratio of 2.00:1.00. Neurocrine granted a security interest in substantially all of its assets, and material domestic subsidiaries will be required to guarantee the obligations. The company has stated it will file the required acquired-business financial statements and pro forma financial information by amendment within 71 calendar days after the initial Form 8-K filing deadline.

May 18, 2026
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (May 5, 2026)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported first-quarter 2026 financial results on May 5, 2026, with total revenues of $814.5 million, compared with $572.6 million in the prior-year period, a 42% increase. Net product sales were $811.0 million, representing 44% year-over-year growth. INGREZZA net product sales were $656.9 million (20% growth year-over-year), and CRENESSITY net product sales were $153.3 million, versus $14.5 million in the first quarter of 2025. GAAP net income was $197.9 million, or $1.91 per diluted share, compared with $7.9 million, or $0.08 per diluted share, a year earlier. Non-GAAP net income was $200.5 million, or $1.94 per diluted share, versus $71.5 million, or $0.70, in the prior-year period. The company reaffirmed its full-year 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion. Full-year GAAP R&D guidance is $1.200 billion to $1.250 billion, and GAAP SG&A guidance is $1.375 billion to $1.400 billion. The guidance excludes post-close expenses from the pending acquisition of Soleno Therapeutics. Operating expenses rose on higher R&D tied to the osavampator and direclidine Phase 3 programs and on expanded commercial sales teams. Cash, cash equivalents, and marketable securities totaled $2,647.2 million at March 31, 2026. A key corporate development is the definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, a total equity value of $2.9 billion, with closing expected in the second quarter of 2026. The company also initiated a Phase 2 study of NBI-1117570 in schizophrenia and a Phase 1 study of NBIP-'2118, a potential obesity therapy. Investors should weigh the strong top-line growth and reaffirmed INGREZZA guidance against rising operating costs and the integration risks of the Soleno transaction.

May 5, 2026
8-K
Material AgreementsExhibits & Filings

Neurocrine Biosciences 8-K Report, Material Agreement (Apr 6, 2026)

On April 5, 2026, Neurocrine Biosciences, Inc. entered into an Agreement and Plan of Merger with Soleno Therapeutics, Inc. under which Neurocrine, through a wholly owned subsidiary, will commence a cash tender offer for all outstanding Soleno shares at $53.00 per share. The press release attached as Exhibit 99.1 describes a total transaction equity value of $2.9 billion, to be funded with cash on hand and a modest amount of pre-payable debt, with no financing condition. The transaction is expected to close within 90 days of the April 6, 2026 announcement, subject to customary conditions including the expiration or termination of the HSR Act waiting period. The offer price represents a premium of approximately 34% to Soleno's April 2, 2026 closing share price and 51% to its 30-day VWAP, according to the press release. The deal centers on VYKAT XR (diazoxide choline), which the filing describes as the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome. The press release states VYKAT XR generated $190 million in 2025 revenue, including $92 million in the fourth quarter. Neurocrine expects the acquisition to add a product to its existing commercial portfolio alongside INGREZZA ($2.51 billion in 2025 revenue) and CRENESSITY ($301 million in 2025 revenue), and to support revenue growth and diversification. The merger agreement includes a $95,250,000 termination fee payable by Soleno in specified circumstances, including to accept a superior proposal, and a $141,500,000 reverse termination fee payable by Neurocrine if the HSR or antitrust-related conditions are not satisfied at termination. Soleno's CEO and Chairman Anish Bhatnagar and former CFO James Mackaness signed Tender and Support Agreements covering approximately 1.01% of outstanding Shares as of April 5, 2026. Soleno's board recommends that stockholders tender their shares.

Apr 6, 2026
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Feb 11, 2026)

Neurocrine Biosciences, Inc. reported fourth-quarter and full-year 2025 results on February 11, 2026, as detailed in Exhibit 99.1. Total net product sales were $798.3 million for the fourth quarter and $2.83 billion for the full year, reflecting year-over-year growth of 29% and 22%, respectively. INGREZZA net product sales were $657.5 million in the fourth quarter and $2.51 billion for the full year, up 7% and 9% year-over-year. CRENESSITY net product sales were $135.3 million in the fourth quarter and $301.2 million for the full year, with 431 and 2,048 total new patient enrollment start forms, respectively. Fourth-quarter GAAP net income was $153.7 million ($1.48 per diluted share), compared with $103.1 million ($1.00) a year earlier. Full-year GAAP net income was $478.6 million ($4.67 per diluted share). Non-GAAP diluted EPS was $1.88 for the fourth quarter and $6.39 for the full year. Cash, cash equivalents, and marketable securities totaled approximately $2.54 billion at December 31, 2025. For 2026, the company guided to INGREZZA net product sales of $2.7 to $2.8 billion, GAAP R&D expense of $1.200 to $1.250 billion, and GAAP SG&A expense of $1.375 to $1.400 billion. Management highlighted advancing Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, along with the initiation of a Phase 2 study of NBI-1065890 in adults with tardive dyskinesia. Operating expense increases in 2025 reflected expanded R&D investment, incremental CRENESSITY launch spending, and upfront payments for early-stage development candidate licenses. The filing notes that the information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act. Investors should review the GAAP-to-non-GAAP reconciliations in the attached tables, since the company excludes items such as stock-based compensation, which totaled $126.9 million in SG&A and $91.0 million in R&D for the full year.

Feb 11, 2026
8-K
Leadership ChangesExhibits & Filings

Neurocrine Biosciences 8-K Report, Executive Changes (Nov 24, 2025)

Neurocrine Biosciences, Inc. (the "Company") filed this Current Report on Form 8-K to disclose an executive compensation and employment matter under Item 5.02. The filing states that Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025. In connection with that transition, the Company and Dr. Roberts entered into an Amended and Restated Employment Agreement effective June 2, 2025, under which Dr. Roberts serves as Strategic Advisor through December 31, 2025. On November 21, 2025, the Company entered into an amendment to that Amended Employment Agreement extending the term of employment for an additional 12-month period, expiring December 31, 2026. The filing describes this only briefly and refers readers to the full amendment, which is filed as Exhibit 10.1. For investors, this is a routine executive-transition disclosure with no financial results, dollar amounts, or operational metrics stated in the filing. Its main significance is governance-related: it confirms the leadership handoff in the Chief Medical Officer role and extends Dr. Roberts's continued involvement with the Company as a strategic advisor through the end of 2026.

Nov 24, 2025
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Oct 28, 2025)

Neurocrine Biosciences, Inc. reported third-quarter 2025 financial results for the quarter ended September 30, 2025, in a press release attached as Exhibit 99.1 to this Form 8-K. Total revenues were $794.9 million, compared with $622.1 million in the third quarter of 2024. Net product sales were $789.9 million, with INGREZZA net product sales of $686.6 million and CRENESSITY net product sales of $98.1 million. GAAP net income was $209.5 million, or $2.04 per diluted share, versus $129.8 million, or $1.24 per diluted share, a year earlier. Non-GAAP net income was $222.1 million, or $2.17 per diluted share, compared with $189.2 million, or $1.81 per diluted share, in the prior-year quarter. GAAP R&D expense rose to $250.0 million from $195.0 million, and GAAP SG&A expense rose to $291.6 million from $234.3 million, reflecting investment in the osavampator and direclidine Phase 3 programs, CRENESSITY launch activities, and the INGREZZA sales team expansion. The company reaffirmed its full-year 2025 INGREZZA net product sales guidance of $2,500 million to $2,550 million and updated its GAAP R&D guidance to $1,000 million to $1,020 million and GAAP SG&A guidance to $1,140 million to $1,160 million. Cash, cash equivalents, and marketable securities totaled $2,113.3 million at September 30, 2025, up from $1,815.6 million at December 31, 2024. The press release also highlighted clinical and corporate developments, including the start of a second Phase 3 registrational trial for direclidine in schizophrenia, new Phase 2 SAVITRI data for osavampator in major depressive disorder, a planned expansion of the INGREZZA and CRENESSITY sales teams to be completed by the end of the first quarter of 2026, and an R&D Day scheduled for December 16, 2025.

Oct 28, 2025
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Jul 30, 2025)

Neurocrine Biosciences, Inc. reported second-quarter 2025 results for the period ended June 30, 2025, with total net product sales of $682 million, which the company describes as 17% year-over-year growth. INGREZZA net product sales were $624 million, up 15% sequentially from the first quarter and 8% year-over-year, and the company said the return to volume growth was driven by strong patient demand and a quarterly record in new prescriptions. CRENESSITY, the company's newer product, generated $53 million in net product sales, with 664 new patient enrollment start forms in the quarter and 76% reimbursement coverage for dispensed scripts. Total revenues were $687.5 million. GAAP net income was $107.5 million, or $1.06 per diluted share, versus $65.0 million, or $0.63 per diluted share, a year earlier. Non-GAAP net income was $166.2 million, or $1.65 per diluted share, compared with $168.9 million, or $1.63, in the prior-year quarter. The company narrowed its 2025 INGREZZA net product sales guidance to $2.5 billion to $2.55 billion, down from $2.5 billion to $2.6 billion, citing double-digit volume growth partially offset by lower net price from expanded access. It also updated full-year GAAP R&D expense guidance to $960 million to $1.01 billion and GAAP SG&A expense guidance to $1.135 billion to $1.155 billion. R&D guidance includes $60 million of development milestone expense tied to collaborations with Takeda and Nxera. Pipeline news was mixed. A Phase 3 study of adjunctive valbenazine in schizophrenia did not meet its primary endpoint, although the company cited consistent trends and a statistically significant effect in the PANSS positive symptom domain. The company initiated a Phase 3 registrational program for NBI-'568, an oral M4 selective muscarinic agonist, in schizophrenia, and began a Phase 1 study of NBIP-1435 for congenital adrenal hyperplasia. Cash, cash equivalents, and marketable securities totaled $1.85 billion at June 30, 2025, and $332 million remained under a $500 million share repurchase program.

Jul 30, 2025
8-K
Leadership ChangesExhibits & Filings

Neurocrine Biosciences 8-K Report, Executive Changes (May 30, 2025)

Neurocrine Biosciences, Inc. filed this Current Report on Form 8-K to disclose a leadership transition in its medical function and related compensatory arrangements. Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025. Dr. Roberts has served as Chief Medical Officer for the past seven years and will remain with the Company in a strategic advisory role following Dr. Keswani's succession. In connection with the transition, the Company entered into an Amended and Restated Employment Agreement with Dr. Roberts on May 30, 2025, effective upon the later of June 2, 2025 and the date the new Chief Medical Officer commences employment. The agreement amends and restates her employment agreement dated February 7, 2025. Under the amended agreement, Dr. Roberts will serve as Strategic Advisor to the CEO from the transition date through December 31, 2025, with an annual base salary of $731,400 and a target annual cash incentive bonus equal to 60% of base pay earned for calendar year 2025. The agreement also provides substantially the same severance benefits she was previously eligible for under the Company's Executive Severance Plan adopted February 7, 2025, and her outstanding equity awards will remain outstanding and continue to vest according to their terms. The filing is primarily an executive-transition disclosure and does not indicate any change to the Company's financial results or guidance.

May 30, 2025
8-K
Leadership ChangesShareholder Matters

Neurocrine Biosciences 8-K Report, Executive Changes (May 22, 2025)

Neurocrine Biosciences, Inc. reported in this Form 8-K, filed May 22, 2025, the results of its 2025 Annual Meeting of Stockholders, held May 21, 2025. The record date was March 24, 2025, when 98,938,234 shares of common stock were entitled to vote. Holders of 90,434,193 shares were present in person or by proxy. Under Item 5.02(e), stockholders approved the company's 2025 Equity Incentive Plan (the "2025 Plan") and an amendment and restatement of the 2018 Employee Stock Purchase Plan (the "Amended and Restated ESPP"). The filing incorporates by reference the summary of these plans' material terms in the definitive proxy statement filed with the SEC on April 9, 2025. Stockholders elected four Class II Directors to three-year terms expiring at the 2028 Annual Meeting: Kyle W. Gano, Ph.D., Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D. Richard F. Pops drew the most votes withheld at 12,809,685, while Kyle W. Gano, Ph.D. drew the fewest at 1,382,673. Class III directors Kevin C. Gorman, Ph.D., Gary A. Lyons, and Johanna Mercier continue until the 2026 meeting, and Class I directors William H. Rastetter, Ph.D., George J. Morrow, Leslie V. Norwalk, and Christine A. Poon continue until the 2027 meeting. The advisory say-on-pay proposal was approved, with 77,981,925 votes for and 6,070,336 against. The 2025 Plan received 72,648,862 votes for and 12,884,104 against, and was approved. The Amended and Restated ESPP received 85,402,588 votes for and 138,042 against, and was approved. Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 85,019,349 votes for and 5,179,700 against. Broker non-votes totaled 4,705,420 on the director, say-on-pay, and 2025 Plan items.

May 22, 2025
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (May 5, 2025)

Neurocrine Biosciences, Inc. reported first-quarter 2025 results for the period ended March 31, 2025, with total revenues of $572.6 million, up from $515.3 million a year earlier. INGREZZA net product sales were $545.2 million, which the company states represents 8% growth compared with the first quarter of 2024, driven by record new patient starts and improved gross-to-net dynamics. CRENESSITY, in its initial launch, generated net product sales of $14.5 million and 413 total patient enrollment start forms. GAAP net income fell to $7.9 million, or $0.08 per diluted share, from $43.4 million, or $0.42 per diluted share. Non-GAAP net income was $71.5 million, or $0.70 per diluted share, compared with $124.8 million, or $1.20 per diluted share. The decline reflects higher R&D and SG&A expense, including a $45 million development milestone in R&D tied to the start of the osavampator Phase 3 program, and a $31 million loss from changes in fair values of equity investments. The company reaffirmed its 2025 guidance, including INGREZZA net product sales of $2.5 to $2.6 billion, GAAP R&D expense of $960 to $1,010 million, and GAAP SG&A expense of $1,110 to $1,130 million. Management highlighted the initiation of two Phase 3 registrational programs, for osavampator in major depressive disorder and NBI-1117568 in schizophrenia, along with Phase 1 studies for NBI-921355 and NBI-1140675. Total cash, cash equivalents, and marketable securities were $1,758.8 million at March 31, 2025, versus $1,815.6 million at December 31, 2024. The company completed a $300 million accelerated share repurchase on February 5, 2025, and had repurchased $150 million under a second $500 million program, with $350 million remaining. The filing also notes the appointment of Sanjay Keswani, M.D., as Chief Medical Officer effective June 2, 2025, and top-line data from the Phase 4 KINECT-PRO study of INGREZZA in tardive dyskinesia. Management described the combination of INGREZZA and CRENESSITY as a solid foundation for near- and long-term revenue growth.

May 5, 2025
8-K
Leadership ChangesRegulation FDExhibits & Filings

Neurocrine Biosciences 8-K Report, Executive Changes (Apr 4, 2025)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) filed this Current Report on Form 8-K on April 4, 2025 to announce a leadership change in its executive team. On April 2, 2025, Sanjay Keswani, M.D. agreed to succeed Eiry W. Roberts, M.D. as Chief Medical Officer, effective June 2, 2025. Dr. Roberts had served as Chief Medical Officer for the past seven years and, as previously announced in July 2023, had decided to retire for personal reasons. She will remain with the Company in a strategic advisory role after the handover. According to the attached press release (Exhibit 99.1), Dr. Keswani has more than 20 years of pharmaceutical industry experience and will lead clinical development and medical affairs. His previous roles include President and CEO of ImmunoBrain, Senior Vice President and R&D Head for Neuroscience, Ophthalmology and Rare Diseases at Hoffman La Roche, and Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb. CEO Kyle W. Gano, Ph.D., said the appointment extends the Company's reach beyond small molecule medicines into new modalities. The press release also credits Dr. Roberts with leading indication expansion for INGREZZA (valbenazine), the crinecerfont program that led to FDA approval of CRENESSITY (crinecerfont), and Phase 2 proof-of-concept studies for osavampator and NBI-1117568, both of which are moving into registrational programs this year.

Apr 4, 2025
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Feb 6, 2025)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported fourth quarter and fiscal 2024 results on February 6, 2025, as furnished under Item 2.02 in Exhibit 99.1. Total revenues for the fourth quarter were $627.7 million, up from $515.2 million, and full-year total revenues were $2,355.3 million, up from $1,887.1 million. INGREZZA fourth-quarter net product sales were $615 million, growing 23%, and fiscal 2024 INGREZZA net product sales were $2.3 billion, growing 26%. CRENESSITY, approved by the FDA in December 2024, generated $2 million in net product sales from initial pharmacy orders. GAAP net income for the fourth quarter was $103.1 million ($1.00 diluted EPS) versus $147.7 million ($1.44) a year earlier, while full-year GAAP net income was $341.3 million ($3.29 diluted EPS) versus $249.7 million ($2.47). Full-year 2024 GAAP results included $138.4 million of charges associated with convertible senior notes and $71.7 million of collaboration development milestone expense. The company guided 2025 INGREZZA net product sales to $2.5 to $2.6 billion, with GAAP R&D expense of $960 to $1,010 million and GAAP SG&A expense of $1,110 to $1,130 million. Guidance includes initiation of Phase 3 programs for osavampator in major depressive disorder and NBI-568 in schizophrenia in the first half of 2025, along with $60 million of expected development milestone expense. Cash, cash equivalents and marketable securities totaled approximately $1.8 billion at December 31, 2024, and the company completed a $300 million accelerated share repurchase in early February 2025, retiring approximately 2.3 million shares in total. Other developments included CMS notification that INGREZZA qualifies for the small biotech exemption under the Medicare Drug Price Negotiation Program, and an amended Takeda collaboration under which Neurocrine will hold exclusive rights to osavampator worldwide except Japan, where Takeda will hold exclusive rights. The company also initiated a Phase 1 study of NBI-921355 for epilepsy and reported KINECT-HD and tardive dyskinesia data for INGREZZA.

Feb 6, 2025
8-K
Material AgreementsRegulation FDExhibits & Filings

Neurocrine Biosciences 8-K Report, Material Agreement (Jan 27, 2025)

On January 24, 2025, Neurocrine Biosciences, Inc. entered into an Amended and Restated Exclusive License Agreement with Takeda Pharmaceutical Company Limited, which amends and restates in its entirety the Exclusive License Agreement dated June 12, 2020. The amendment converts the arrangement for osavampator (NBI-1065845 / TAK-653), a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder, from a shared operating profit and loss structure to a royalty-bearing license. Neurocrine will hold exclusive worldwide development and commercialization rights to osavampator for all indications, excluding Japan, where Takeda will reacquire exclusive rights. Each party will bear development costs in its own territory and is eligible to receive royalties on the other party's net sales in that territory. Takeda is now eligible for development and commercial milestones, as contemplated in the original agreement. The filing also states that the company previously terminated the DAAO inhibitors under the original agreement, including luvadaxistat, and the GPR139 agonists, including NBI-1070770 (listed as NBI-1065846 in the filing). Neurocrine stated that, upon successful development and commercialization of osavampator, it expects tiered royalties payable to Takeda in the mid-to-upper teens in the United States and low double-digits outside the United States, on a blended basis as a percentage of net sales. The company would also be entitled to royalties from Takeda on net sales in Japan. Neurocrine's CEO, Kyle Gano, Ph.D., said the company had completed its End-of-Phase 2 meeting with the FDA for osavampator and expects to begin the Phase 3 program in the first half of 2025. The full agreement will be filed as an exhibit to the company's Form 10-Q for the period ending March 31, 2025, with confidential terms redacted. The Regulation FD press release announcing the agreement is furnished as Exhibit 99.1.

Jan 27, 2025
8-K
Other Events

Neurocrine Biosciences 8-K Report, Corporate Update (Dec 20, 2024)

On December 20, 2024, Neurocrine Biosciences, Inc. filed a Form 8-K under Item 8.01 (Other Events) announcing that CRENESSITY (crinecerfont) capsules and oral solution are now available in the United States. The drug was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH). The filing attaches a press release (Exhibit 99.1) describing CRENESSITY as a first-in-class oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist. The Company has set a wholesale acquisition cost of approximately $38,333 for a 30-day supply in the United States, and approximately $19,167 for a 30-day supply for pediatric patients weighing less than 20 kilograms. The Company expects 90% of patients will have a monthly copay of $12 or less. Access is centralized through PANTHERx Rare, a specialty pharmacy, and the Company offers a free patient assistance program, Neurocrine Access Support. The filing's forward-looking statements flag risks including adequate third-party reimbursement, the Company's dependence on third parties for development and manufacturing, and the commercialization of CRENESSITY. The press release states that the approval was supported by the CAHtalyst Pediatric study (103 patients aged four to 17) and the CAHtalyst Adult study (182 patients aged 18 to 58), and that the open-label extension portions of both studies are ongoing.

Dec 20, 2024
8-K
Other Events

Neurocrine Biosciences 8-K Report, Corporate Update (Nov 1, 2024)

Neurocrine Biosciences, Inc. reported in this Form 8-K, filed November 1, 2024, that on October 31, 2024 it entered into an accelerated share repurchase (ASR) agreement with Goldman Sachs & Co. LLC to repurchase $300.00 million of its common stock. The ASR is being completed under a previously announced $300.00 million share repurchase program authorized by the Board of Directors. Under the ASR Agreement, the company will pay the $300.00 million Repurchase Price on November 4, 2024 and receive common stock with an aggregate value equal to 80% of that price, based on the October 31, 2024 closing share price. The final number of shares will be based on volume-weighted average prices over the transaction term, less a discount, subject to adjustments. At final settlement, Neurocrine may receive additional shares from Goldman Sachs or, in certain circumstances, may have to deliver shares or make a cash payment at its option. The ASR agreement includes customary provisions, including adjustment, acceleration, extension and early termination terms, along with representations and warranties. The transaction is scheduled to terminate in the first quarter of 2025.

Nov 1, 2024
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Oct 30, 2024)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported third quarter 2024 results on October 30, 2024, per Exhibit 99.1 to this Form 8-K. Third quarter total revenues were $622.1 million, versus $498.8 million in the third quarter of 2023, with net product sales of $616.6 million. INGREZZA third quarter net product sales were $613 million, growing 26% year over year, driven by underlying patient demand and improved gross-to-net dynamics. GAAP net income was $129.8 million, or $1.24 per diluted share, compared with $83.1 million, or $0.82, a year earlier. Non-GAAP net income was $189.2 million, or $1.81 per diluted share. Cash, cash equivalents and marketable securities totaled $1,871.9 million at September 30, 2024. The company raised its 2024 INGREZZA net product sales guidance to $2.30 to $2.32 billion and updated its expense guidance. GAAP R&D is now expected at $700 to $720 million and GAAP SG&A at $970 to $990 million. Management cited investments in R&D, the expanded psychiatry and long-term care sales teams, and pre-launch activities for crinecerfont, which has a Priority Review from the FDA in congenital adrenal hyperplasia. The Board authorized a $300 million share repurchase plan, and the company intends to enter a $300 million accelerated share repurchase transaction in the coming days, subject to market conditions. The filing also discloses pipeline and leadership developments. Kyle W. Gano, Ph.D. became Chief Executive Officer effective October 11, 2024. The Phase 2 study of NBI-1117568, an M4 agonist for schizophrenia, was positive and triggered a $35 million milestone payment to Nxera, with Phase 3 initiation expected in the first half of 2025. The luvadaxistat Phase 2 ERUDITE study missed its primary endpoint, and the company has given notice to terminate that license with Takeda, effective April 2025.

Oct 30, 2024
8-K
Leadership Changes

Neurocrine Biosciences 8-K Report, Executive Changes (Oct 11, 2024)

Neurocrine Biosciences, Inc. filed this Form 8-K under Item 5.02 to disclose an Amended and Restated Employment Agreement with Kyle Gano, Ph.D., entered into on October 11, 2024, in connection with a previously announced leadership transition. Under the agreement, Dr. Gano becomes President and Chief Executive Officer effective October 11, 2024, with an annual base salary of $900,000 and an initial target annual cash incentive bonus equal to 100% of base pay earned for the applicable year. Dr. Gano will receive promotion equity grants under the 2020 Equity Incentive Plan, as amended: stock options with a target grant value of approximately $750,000 vesting in equal monthly installments over four years, restricted stock units with a target grant value of approximately $300,000 vesting in equal annual installments over four years, and performance-vesting restricted stock units with a target grant value of approximately $450,000 vesting under the terms of the March 2024 executive PRSU grants. These grants are scheduled to be made automatically two business days after the filing of the company's first Form 10-Q following the Effective Date, provided he remains employed, with share numbers set by the grant-date stock price. The agreement also sets severance terms. Outside a change in control determination period (from a change in control through 12 months after), a termination without cause or resignation for good reason triggers 1.5 times the sum of base salary and target bonus, a pro rata actual bonus, up to 18 months of health premiums, and vesting over a 15-month period, with discretionary vesting of performance awards. Within that period, the multiple rises to 2 times, with a pro rata target bonus, up to 24 months of health premiums, and full equity vesting, with performance awards vesting at the greater of target or actual. Death or disability triggers full equity vesting. The full agreement will be filed as an exhibit to a subsequent SEC filing.

Oct 11, 2024
8-K
Regulation FDOther EventsExhibits & Filings

Neurocrine Biosciences 8-K Report, Regulation FD Disclosure (Aug 28, 2024)

Neurocrine Biosciences, Inc. reported positive top-line data from its Phase 2 NBI-'568-SCZ2028 dose-finding study of NBI-'568 (NBI-1117568) in adults with schizophrenia experiencing an acute exacerbation or relapse. The once-daily 20 mg dose met the primary endpoint, with a placebo-adjusted mean reduction of 7.5 points in PANSS total score at Week 6 (p=0.011, effect size 0.61) and an 18.2-point reduction from baseline. The 20 mg dose also showed statistically significant improvements on CGI-S and Marder Factor Scores for positive and negative symptoms. The 40 mg once-daily, 60 mg once-daily, and 30 mg twice-daily arms did not reach statistical significance on the primary endpoint versus placebo (p=0.282, p=0.189, and p=0.090, respectively). The company stated that NBI-'568 was generally safe and well tolerated at all doses studied. Treatment discontinuation rates due to adverse events were 5.0% across all NBI-'568 arms versus 4.3% for placebo, according to the slide presentation. The most common adverse events were somnolence, dizziness, and headache. Gastrointestinal events, cardiovascular-related events, and extrapyramidal symptoms were reported at low frequency, and NBI-'568 was not associated with greater weight gain than placebo. Neurocrine expects to advance NBI-'568 into Phase 3 development in schizophrenia in early 2025. The filing describes NBI-'568 as the first investigational, oral, muscarinic M4 selective agonist in development for schizophrenia. Neurocrine also noted a broader muscarinic portfolio, including NBI-1117567, NBI-1117569, and NBI-1117570, which it acquired from Nxera Pharma (formerly Sosei Heptares), and NBI-1076986, an internally developed M4 antagonist. The filing includes forward-looking statement cautions noting that top-line data may change after more comprehensive review.

Aug 28, 2024
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Aug 1, 2024)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported second quarter 2024 results on August 1, 2024, as furnished under Item 2.02 of this Form 8-K (Exhibit 99.1 press release). Total revenues for the quarter were $590.2 million, up from $452.7 million in the second quarter of 2023, with net product sales of INGREZZA at $583.8 million (the press release describes INGREZZA second quarter net sales as $580 million, growing 32% year over year). GAAP net income was $65.0 million, or $0.63 per diluted share, versus $95.5 million, or $0.95 per diluted share, a year earlier. Non-GAAP net income was $168.9 million, or $1.63 per diluted share, compared with $125.7 million, or $1.25, in the prior-year quarter. GAAP results were affected by a $49.7 million charge tied to convertible senior notes conversion settlements, a $19.9 million loss on equity security investments, $27 million of development milestones expensed under collaborations, and a $14 million leased office impairment. The company raised its 2024 INGREZZA net product sales guidance to $2.25 billion to $2.3 billion. Updated 2024 expense guidance calls for GAAP R&D of $665 million to $695 million, non-GAAP R&D of $600 million to $630 million, GAAP SG&A of $955 million to $975 million, and non-GAAP SG&A of $830 million to $850 million. Cash, cash equivalents and marketable securities totaled approximately $1.7 billion at June 30, 2024 ($1,676.7 million), after a $309 million payment to fully retire the convertible senior notes. Leadership news is significant: CEO Kevin Gorman, Ph.D. will retire on October 11, 2024, and Kyle Gano, Ph.D., currently Chief Business Development and Strategy Officer, will succeed him and join the Board. The company also reported positive topline Phase 2 SAVITRI data for NBI-1065845 in major depressive disorder, FDA acceptance and Priority Review for crinecerfont in congenital adrenal hyperplasia with PDUFA dates of December 29 and 30, 2024, and Phase 2 top-line data for NBI-1117568 and luvadaxistat expected in Q3 2024.

Aug 1, 2024
8-K
Leadership ChangesCorporate ChangesExhibits & Filings

Neurocrine Biosciences 8-K Report, Executive Changes (May 28, 2024)

On May 28, 2024, Neurocrine Biosciences, Inc. ("Neurocrine") announced that Kevin C. Gorman, Ph.D. will retire as President and Chief Executive Officer effective October 11, 2024 (the "Transition Date"). Dr. Gorman notified the company of his planned retirement on May 24, 2024, and will remain on the Board of Directors as a member. The company also announced that Kyle Gano, Ph.D., age 51, will succeed him as President and Chief Executive Officer effective on the Transition Date. Dr. Gano will also join the Board as a Class II director, to serve until the 2025 annual meeting of stockholders. The filing states that he has served as Chief Business Development Officer since 2011 and as Chief Business Development and Strategy Officer since 2020, with responsibility for all business and corporate development activities, including collaborations with AbbVie, Mitsubishi Tanabe Pharma, Takeda, Xenon Pharmaceuticals, Voyager Therapeutics, and others. He joined Neurocrine in 2001. Effective on the Transition Date, the Board amended Section 3.2 of the Bylaws to increase the authorized size of the Board from ten to eleven members, with the new seat filled by Dr. Gano's appointment. The amendment is filed as Exhibit 3.1.

May 28, 2024
8-K
Leadership ChangesShareholder Matters

Neurocrine Biosciences 8-K Report, Executive Changes (May 23, 2024)

Neurocrine Biosciences, Inc. filed this Form 8-K on May 23, 2024 to report the results of its 2024 Annual Meeting of Stockholders, held on May 22, 2024. Stockholders approved an amendment to the Company's 2020 Equity Incentive Plan (the Amended 2020 Plan), and the summary of its material terms is set forth in the definitive proxy statement filed with the SEC on April 10, 2024. Of the 100,580,497 shares of common stock entitled to vote as of the March 25, 2024 record date, 90,166,107 shares were present in person or by proxy. Stockholders voted on four matters. All four nominees for Class I Director (William H. Rastetter, Ph.D., George J. Morrow, Leslie V. Norwalk, and Christine A. Poon) were elected to three-year terms expiring at the 2027 Annual Meeting. The advisory vote on named executive officer compensation passed with 80,281,842 votes for and 4,276,395 against. The Amended 2020 Plan was approved with 76,076,416 votes for and 9,499,523 against. The appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2024 was ratified with 84,641,389 votes for and 5,451,051 against. For investors, the filing is primarily governance-related and reports no new financial results, transactions, or changes in leadership beyond the director elections. The most notable item is the approval of the Amended 2020 Plan, which the Company describes only by reference to its proxy statement, and the Plan's specific terms are not stated in this filing.

May 23, 2024
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (May 1, 2024)

Neurocrine Biosciences, Inc. reported first quarter 2024 results in a press release furnished under Item 2.02 of this Form 8-K (Exhibit 99.1). Total revenues were $515.3 million, up from $420.4 million in the first quarter of 2023, with net product sales of $509.0 million. INGREZZA first quarter net product sales were $506 million, which the company said grew 23% year over year, driven by strong underlying patient demand and improved gross-to-net dynamics. GAAP net income was $43.4 million, or $0.42 per diluted share, compared with a GAAP net loss of $76.6 million, or $0.79 per share, in the prior-year quarter. Non-GAAP net income was $124.8 million, or $1.20 per diluted share. The first quarter 2024 GAAP results include an $89 million charge tied to the company's election to settle its convertible senior notes in cash. The company reaffirmed its 2024 INGREZZA net product sales guidance of $2,100 million to $2,200 million and updated its expense guidance, with GAAP R&D expense of $665 million to $695 million and GAAP SG&A expense of $920 million to $940 million. GAAP R&D guidance includes approximately $34 million of development milestone expense tied to collaborations. Cash, cash equivalents and marketable securities totaled $1,911.0 million at March 31, 2024, compared with $1,719.1 million at December 31, 2023. Pipeline progress included the April 2024 submission of two New Drug Applications to the FDA for crinecerfont in adult and pediatric classic congenital adrenal hyperplasia, FDA approval of INGREZZA SPRINKLE capsules on April 30, 2024, and positive Phase 2 top-line data for NBI-1065845 in major depressive disorder, where the company is engaging with the FDA on a path forward. The company also expects top-line Phase 2 data for NBI-1117568 and luvadaxistat in the third quarter of 2024.

May 1, 2024
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Feb 7, 2024)

Neurocrine Biosciences, Inc. reported fourth-quarter and full-year 2023 results on February 7, 2024, with INGREZZA (valbenazine) driving growth. Fourth-quarter total revenues were $515.2 million, and full-year total revenues were $1,887.1 million, compared with $1,488.7 million in 2022. INGREZZA net product sales were $500 million in the fourth quarter, up 25% year over year, and $1.84 billion for the full year, up 29%. Full-year GAAP net income was $249.7 million, or $2.47 per diluted share, versus $154.5 million, or $1.56 per diluted share, in 2022. Full-year non-GAAP net income was $390.0 million, or $3.86 per diluted share. Cash, cash equivalents and marketable securities totaled $1,719.1 million at December 31, 2023. For 2024, the company guided to INGREZZA net product sales of $2.1 billion to $2.2 billion, GAAP R&D expense of $645 million to $675 million, and GAAP SG&A expense of $930 million to $950 million. The guidance also states that SG&A reflects pre-launch commercial activities for crinecerfont. The company expects to submit a New Drug Application for crinecerfont to the FDA in the second quarter of 2024, following positive Phase 3 results in congenital adrenal hyperplasia. Crinecerfont received Breakthrough Therapy designation in December 2023. A PDUFA date of April 30, 2024 is listed for the sprinkle formulation of valbenazine. Recent developments include the resolution of all patent litigation against companies that filed ANDAs for generic versions of INGREZZA. Those companies may sell generic versions beginning March 2038, or earlier under certain circumstances. The filing also lists a series of 2024 pipeline milestones, including Phase 2 data readouts for several programs in the first and second halves of 2024.

Feb 7, 2024
8-K
Other Events

Neurocrine Biosciences 8-K Report, Corporate Update (Nov 13, 2023)

On November 10, 2023, Neurocrine Biosciences, Inc. entered into an agreement with Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Limited (collectively, "Zydus") to resolve patent litigation over INGREZZA®, the Company's medication for tardive dyskinesia and chorea associated with Huntington's disease. The litigation arose after Zydus notified the Company that it had submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market generic versions of INGREZZA before the expiration of the Company's Orange Book listed patents. Under the agreement, the Company has granted Zydus the right to sell generic INGREZZA in the United States beginning October 1, 2038, or earlier under certain circumstances. The Company previously reached similar settlements with Sandoz Inc. and Crystal Pharmaceutical (Suzhou) Co., Ltd. and Crystal Pharmatech Co., Ltd. (the "Sandoz Parties"), Teva Pharmaceuticals entities, and Lupin Limited and Lupin Pharmaceuticals, Inc. Those agreements give Teva, the Sandoz Parties, and Lupin the right to sell generic INGREZZA beginning March 1, 2038, or earlier under certain circumstances. The Company states that the settlements with Teva, the Sandoz Parties, Lupin, and Zydus together resolve all patent litigation it brought against companies that filed ANDAs seeking to market generic INGREZZA. The filing states that the Zydus Agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice, as required by law. The filing does not include any financial results, revenue figures, or financial projections.

Nov 13, 2023
8-K
Other Events

Neurocrine Biosciences 8-K Report, Corporate Update (Nov 9, 2023)

Neurocrine Biosciences, Inc. disclosed in a Current Report on Form 8-K (Item 8.01, Other Events) that on November 9, 2023 it entered into an agreement with Lupin Limited and Lupin Pharmaceuticals, Inc. (together, "Lupin") to resolve patent litigation over INGREZZA, its medication for tardive dyskinesia and chorea associated with Huntington's disease. The litigation had been filed by the Company in the U.S. District Court for the District of Delaware after Lupin notified it of an Abbreviated New Drug Application (ANDA) seeking approval to market generic INGREZZA before the expiration of Orange Book-listed patents. Under the settlement, the Company has granted Lupin the right to sell generic versions of INGREZZA in the United States beginning March 1, 2038, or earlier under certain circumstances. The agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice, as required by law. The filing also states that similar patent litigation against the remaining company that filed an ANDA for generic INGREZZA remains pending, with a trial date set for January 2, 2024. The filing notes that the Company previously settled similar litigation with Sandoz Inc. and Crystal Pharmaceutical (Suzhou) Co., Ltd. and Crystal Pharmatech Co., Ltd. (together, the "Sandoz Parties") and with Teva Pharmaceuticals entities. Each of Teva and the Sandoz Parties also has the right to sell generic INGREZZA in the United States beginning March 1, 2038, or earlier under certain circumstances, so the Lupin settlement aligns generic entry timing across the settled challengers.

Nov 9, 2023
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Oct 31, 2023)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported third quarter 2023 results for the period ended September 30, 2023, and raised its 2023 INGREZZA net product sales guidance to $1.82 billion to $1.84 billion. INGREZZA third quarter net product sales were $486 million, growing 29% year over year on prescription demand. Total revenues for the quarter were $498.8 million, compared with $387.9 million in the third quarter of 2022. GAAP net income was $83.1 million, or $0.82 per diluted share, versus $68.5 million, or $0.69 per diluted share, a year earlier. Non-GAAP net income was $156.1 million, or $1.54 per diluted share, compared with $106.7 million, or $1.08 per diluted share. The company cited higher R&D spending on its expanded clinical portfolio and higher SG&A spending on INGREZZA commercial initiatives, including the new Huntington's disease chorea indication. The company reported cash, cash equivalents and marketable securities of approximately $1.5 billion at September 30, 2023. Updated 2023 guidance includes GAAP R&D expense of $560 million to $570 million, GAAP SG&A expense of $870 million to $890 million, and acquired in-process R&D of $144 million, which includes $143.9 million associated with a new strategic collaboration with Voyager. The filing also notes positive Phase 3 CAHtalyst top-line results for crinecerfont in adults (September 2023) and pediatric patients (October 2023) with congenital adrenal hyperplasia, and an Analyst Day in New York City on December 5, 2023.

Oct 31, 2023
8-K
Other Events

Neurocrine Biosciences 8-K Report, Corporate Update (Oct 6, 2023)

Neurocrine Biosciences, Inc. reported in an 8-K filed October 6, 2023 that on October 5, 2023 it entered into an agreement with Sandoz Inc. and Crystal Pharmaceutical (Suzhou) Co., Ltd. and Crystal Pharmatech Co., Ltd. (together, the "Sandoz Parties") resolving patent litigation over INGREZZA, its medication for tardive dyskinesia and chorea associated with Huntington's disease. The litigation had been filed by the Company in the U.S. District Court for the District of Delaware after the Sandoz Parties notified the Company that they had submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market generic versions of INGREZZA before expiration of the Company's Orange Book listed patents. Under the settlement, the Company has granted the Sandoz Parties the right to sell generic versions of INGREZZA in the United States beginning February 1, 2040, or earlier under certain circumstances. The agreement must be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice, as required by law. Similar patent litigation against the two remaining companies that filed ANDAs for generic INGREZZA remains pending, with a trial date set for January 2, 2024. For investors, the key items are the defined generic entry date under the Sandoz settlement and the open litigation with the other two ANDA filers.

Oct 6, 2023
8-K
Other EventsExhibits & Filings

Neurocrine Biosciences 8-K Report, Corporate Update (Oct 5, 2023)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) filed this Form 8-K on October 5, 2023 under Item 8.01 (Other Events) to furnish a press release announcing top-line results from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and adolescents (ages 2–17) with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study met its primary endpoint, showing a statistically significant decrease in serum androstenedione from baseline at Week 4 versus placebo (p = 0.0002), and met a key secondary endpoint: a statistically significant percent reduction in daily glucocorticoid (GC) dose while maintaining androgen control at Week 28 versus placebo (p < 0.0001). Approximately 30% of crinecerfont-treated participants achieved a reduction to a physiologic GC dose while maintaining androgen control, compared with 0% on placebo. The company also reported a statistically significant decrease in serum 17-hydroxyprogesterone at Week 4 (p < 0.0001). The company stated that crinecerfont was generally well tolerated, with the most common adverse events being headache, fever, vomiting, upper respiratory tract infection, and nasopharyngitis, few serious adverse events, and none assessed as related to crinecerfont. Completion of the 28-week double-blind period exceeded 95%. Management cited the results, together with the CAHtalyst Adult study results reported the previous month, as supporting crinecerfont's potential as a new standard of care that reduces androgen levels through a non-glucocorticoid mechanism. The company said data from both CAHtalyst studies, including open-label periods, will support regulatory submissions to the FDA in 2024 and later to the European Medicines Agency, with further detail planned for the December 2023 Analyst Day and a peer-reviewed journal publication. The filing notes that top-line data may change following a more comprehensive review.

Oct 5, 2023
8-K
Other EventsExhibits & Filings

Neurocrine Biosciences 8-K Report, Corporate Update (Sep 12, 2023)

Neurocrine Biosciences, Inc. filed this Form 8-K on September 12, 2023 under Item 8.01 (Other Events) to announce top-line results from the Phase 3 CAHtalyst Adult Study of crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The attached press release (Exhibit 99.1) states that the study met its primary endpoint at Week 24, showing a statistically significant percent reduction in daily glucocorticoid dose versus placebo while maintaining androgen control (p-value <0.0001). The company also reported a statistically significant decrease in androstenedione at Week 4 versus placebo and a higher share of patients reaching a physiologic glucocorticoid dose at Week 24 (approximately 63% on crinecerfont versus approximately 18% on placebo). The filing states that crinecerfont was generally well tolerated, with the most common adverse events being fatigue, headache, and coronavirus infection, and none of the few serious adverse events assessed as related to crinecerfont. The study enrolled 182 patients and is followed by one year of open-label treatment. Management stated that these data, together with open-label period data, will support regulatory submissions to the U.S. FDA in 2024 and to the European Medicines Agency afterward. Data from the separate CAHtalyst Pediatric Study are expected in early Q4 2023, as planned. For investors, the key takeaways are the positive primary and key secondary endpoint results, the company's stated regulatory timeline, and the upcoming pediatric data readout. The press release notes that additional detail would be presented at the Morgan Stanley 21st Annual Global Healthcare Conference and that further data will be provided in a peer-reviewed journal or at a medical conference at a later date.

Sep 12, 2023
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Aug 1, 2023)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported financial results for the second quarter ended June 30, 2023, and raised its 2023 INGREZZA net product sales guidance to $1.77 - $1.82 billion, according to the press release attached as Exhibit 99.1 to this Form 8-K filed August 1, 2023. Second quarter net product sales were $446.3 million on total revenues of $452.7 million, versus $378.2 million in the prior-year quarter. INGREZZA second quarter net product sales were $440 million, growing 26% year over year, driven by prescription demand, and the company cited a record number of new patients receiving therapy during the quarter. GAAP net income for the second quarter of 2023 was $95.5 million, or $0.95 per diluted share, compared with a GAAP net loss of $16.9 million, or $0.18 per share, in the second quarter of 2022, which included a $70.0 million loss on extinguishment of debt. Non-GAAP net income was $125.7 million, or $1.25 per diluted share, versus $82.1 million, or $0.84 per share, a year earlier. Cash, cash equivalents and marketable securities were $1,319.3 million at June 30, 2023 (the balance sheet table shows $976.7 million in cash, cash equivalents and marketable securities, with additional debt securities classified separately). Looking ahead, management highlighted a PDUFA date of August 20, 2023 for valbenazine in chorea associated with Huntington's disease and four pipeline read-outs expected in the fourth quarter of 2023, including Phase 3 registrational data for crinecerfont in pediatric and adult congenital adrenal hyperplasia. Reaffirmed 2023 GAAP R&D guidance is $550-$580 million and GAAP SG&A guidance is $850-$870 million. The filing states that the information is furnished and not deemed filed under Section 18 of the Exchange Act.

Aug 1, 2023
8-K
Leadership Changes

Neurocrine Biosciences 8-K Report, Executive Changes (Jul 13, 2023)

Neurocrine Biosciences, Inc. (the Company) filed this Current Report on Form 8-K dated July 13, 2023 under Item 5.02, disclosing a leadership transition. On July 10, 2023, Eiry W. Roberts, M.D. notified the Company of her decision to retire in 2025 from her position as Chief Medical Officer. Dr. Roberts has not yet set her last day of employment and will remain in the role until her replacement has been onboarded. The Company has initiated a search for a replacement Chief Medical Officer. According to the filing, Dr. Roberts is retiring for personal reasons and not because of any disagreement with the Company on matters relating to its operations, policies or practices. The filing is largely procedural. It contains standard forward-looking statements, including those covering Dr. Roberts' retirement plans and the search for a successor, and refers readers to the risk factors in the Company's Form 10-Q for the quarter ended March 31, 2023.

Jul 13, 2023
8-K
Leadership ChangesCorporate Changes

Neurocrine Biosciences 8-K Report, Executive Changes (Jul 12, 2023)

Neurocrine Biosciences, Inc. (Delaware corporation) filed this Form 8-K reporting two governance actions taken by its Board of Directors on July 11, 2023. First, the Board appointed Christine A. Poon as a Class I director, effective immediately, to serve until the 2024 annual meeting of stockholders, upon the recommendation of the Nominating / Corporate Governance Committee. Ms. Poon is a former Vice Chairman and Board member of Johnson & Johnson, former Dean of the Max M. Fisher College of Business at The Ohio State University, and currently sits on the boards of Prudential Financial, Inc., The Sherwin-Williams Company, and serves as lead independent director of Regeneron Pharmaceuticals, Inc. Second, the Board amended Section 3.2 of the Bylaws to increase the size of the Board from nine to ten members. The newly created vacancy was filled by Ms. Poon's appointment. The amendment is filed as Exhibit 3.1, a Certificate of Amendment of Bylaws. For compensation, Ms. Poon will receive a $60,000 annual cash retainer and a nonstatutory stock option to purchase 16,375 shares of common stock, with a Black-Scholes value of approximately $800,000. The option has an exercise price equal to the July 11, 2023 closing price, a ten-year term, and vests monthly over three years. The Company stated it is not aware of any related-person transaction requiring disclosure under Item 404(a) of Regulation S-K.

Jul 12, 2023
8-K
Leadership ChangesShareholder Matters

Neurocrine Biosciences 8-K Report, Executive Changes (May 19, 2023)

Neurocrine Biosciences, Inc. filed this Form 8-K to report the results of its 2023 Annual Meeting of Stockholders, held on May 17, 2023. Of the 97,525,642 shares of common stock entitled to vote as of the March 20, 2023 record date, 86,527,005 shares were present in person or by proxy. Stockholders elected three Class III Directors (Kevin C. Gorman, Gary A. Lyons and Johanna Mercier) to terms expiring at the 2026 Annual Meeting, approved an advisory vote on named executive officer compensation, approved the Amended 2020 Equity Incentive Plan, and ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2023. On the say-on-pay frequency proposal, 99.01% of voted shares favored an annual vote, and the Company stated it will hold future say-on-pay votes annually until the next frequency vote. On the executive compensation advisory vote, 93.11% of voted shares were For and 6.82% Against, so the compensation was approved on an advisory basis. The Amended 2020 Plan received 84.95% For and 14.96% Against, and the plan was approved. The filing incorporates by reference the summary of the Amended 2020 Plan's material terms from the definitive proxy statement filed with the SEC on April 5, 2023. For investors, the filing shows broad stockholder support for management's proposals, with the plan amendment being the most contested item, and it confirms the annual cadence for future say-on-pay votes.

May 19, 2023
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (May 3, 2023)

Neurocrine Biosciences, Inc. reported first quarter 2023 results on May 3, 2023. Total revenues were $420.4 million, up from $310.6 million in the first quarter of 2022, driven by product sales, net of $415.3 million. INGREZZA (valbenazine) first quarter net product sales were $410 million, and the company reported a record number of new patients receiving therapy during the quarter. The company reported a GAAP net loss of $76.6 million, or $0.79 per diluted share, compared with GAAP net income of $13.9 million, or $0.14 per diluted share, a year earlier. The loss was driven in part by $143.9 million of acquired in-process R&D expense tied to the expanded strategic partnership with Voyager Therapeutics. On a non-GAAP basis, the net loss was $49.5 million, or $0.51 per diluted share. The company reiterated its 2023 INGREZZA net product sales guidance of $1.67 billion to $1.77 billion and provided 2023 GAAP R&D guidance of $550 million to $580 million and GAAP SG&A guidance of $850 million to $870 million. Cash, cash equivalents and marketable securities were $1,139.2 million at March 31, 2023, compared with $1,288.7 million at December 31, 2022. Management highlighted an August 20, 2023 PDUFA date for valbenazine in chorea associated with Huntington disease, and top-line data expected in the second half of 2023 for several programs, including crinecerfont in congenital adrenal hyperplasia. The company also disclosed that it provided BIAL with written notice to terminate the license to commercialize ONGENTYS (opicapone) in the United States and Canada, citing that continued commercialization is unsustainable. The termination is anticipated to be effective in December 2023. The Voyager collaboration, which became effective February 21, 2023, involved up-front consideration of $175 million for worldwide rights to Voyager's GBA1 gene therapy program and three rare CNS gene therapy programs.

May 3, 2023
8-K
Other Events

Neurocrine Biosciences 8-K Report, Corporate Update (Mar 29, 2023)

Neurocrine Biosciences, Inc. disclosed in a Form 8-K filed March 29, 2023 that on March 28, 2023 it entered into an agreement with Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. resolving patent litigation over INGREZZA, its medication for tardive dyskinesia. The litigation arose after Teva notified the company that it had submitted an Abbreviated New Drug Application to the FDA seeking approval to market generic versions of INGREZZA before the expiration of the company's Orange Book listed patents. Under the settlement, Neurocrine granted Teva the right to sell generic versions of INGREZZA in the United States beginning February 1, 2040, or earlier under certain circumstances. The agreement must be submitted to the Federal Trade Commission and the Department of Justice, as required by law. Neurocrine's separate patent litigation against three other companies that filed ANDAs for generic INGREZZA remains pending, with a trial date set for January 2, 2024. The filing does not state financial terms of the Teva settlement.

Mar 29, 2023
8-K
Other Events

Neurocrine Biosciences 8-K Report, Corporate Update (Feb 24, 2023)

Neurocrine Biosciences, Inc. disclosed that its Collaboration and License Agreement with Voyager Therapeutics Limited, entered into on January 8, 2023, became effective on February 21, 2023, after the waiting periods under the Hart-Scott Rodino Antitrust Improvements Act of 1976 expired. The agreement was previously described in the company's January 9, 2023 Form 8-K. On February 23, 2023, the company paid Voyager an upfront payment of approximately $136.0 million under the collaboration agreement. The company also purchased 4,395,588 shares of Voyager common stock at $8.88 per share, for an aggregate purchase price of approximately $39.0 million, under the 2023 Stock Purchase Agreement entered into on January 8, 2023. In connection with the transaction, the parties amended and restated their existing investor agreement. Under that amended agreement, Voyager appointed Jude Onyia, Ph.D., Neurocrine's Chief Scientific Officer, to Voyager's board of directors.

Feb 24, 2023
8-K
Corporate ChangesExhibits & Filings

Neurocrine Biosciences 8-K Report, Bylaw Amendment (Feb 10, 2023)

Neurocrine Biosciences, Inc. filed this Current Report on Form 8-K to disclose an amendment to its bylaws. On February 9, 2023, the Board of Directors amended and restated the Company's Bylaws (the "Restated Bylaws"), effective immediately upon adoption. The filing describes the changes as governance matters rather than financial results; the filing contains no financial figures. The most significant change is the addition of a proxy access provision. Under it, a stockholder or a group of no more than 20 stockholders owning three percent or more of the Company's voting power, held continuously for at least three years, may nominate director candidates for inclusion in the company's proxy statement. The number of nominees is capped at the greater of two individuals or 20% of directors in office, and may not exceed 50% of the directors in the class whose term expires at that annual meeting, subject to procedural and disclosure requirements. The Restated Bylaws also tighten procedures for stockholder nominations, other business proposals, and actions by written consent. Among other things, they require expanded disclosures about proposing stockholders and nominees, compliance with Rule 14a-19 under the Securities Exchange Act of 1934 for dissident proxy solicitations, and updates to disclosures before the meeting record date and five business days prior to the meeting. Nominees of stockholders who fail to meet these requirements will be disregarded. The filing also notes ministerial and conforming changes to align with the Delaware General Corporation Law.

Feb 10, 2023
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Feb 6, 2023)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported financial results for the fourth quarter and fiscal year ended December 31, 2022, and provided financial guidance for 2023, per this Form 8-K dated February 6, 2023. For the fourth quarter, total revenues were $412.0 million (versus $312.0 million in the prior-year quarter), driven by INGREZZA net product sales of $399 million, which grew 33% year over year, with total prescriptions up 29%. GAAP net income was $89.0 million, or $0.88 per diluted share, compared with a GAAP net loss of $7.3 million, or $0.08 per diluted share, in the fourth quarter of 2021. For fiscal 2022, total revenues were $1,488.7 million and GAAP net income was $154.5 million, or $1.56 per diluted share. Cash, cash equivalents and marketable securities were approximately $1.3 billion at December 31, 2022. For 2023, the company guided to INGREZZA (tardive dyskinesia only) net product sales of $1.67 to $1.77 billion, GAAP R&D expense of $550 to $580 million, and GAAP SG&A expense of $850 to $870 million. Management highlighted enrollment completion in the adult and pediatric registrational studies of crinecerfont for congenital adrenal hyperplasia, with top-line data expected in the second half of 2023. The company also noted an FDA PDUFA target action date of August 20, 2023 for valbenazine in chorea associated with Huntington disease, and announced a planned Voyager Therapeutics collaboration expected to close in the first quarter of 2023, subject to regulatory conditions. The filing also reports a $70.0 million loss on extinguishment of convertible senior notes in 2022 related to a partial repurchase, and a $55 million all-cash acquisition of Diurnal Group plc completed November 1, 2022. Non-GAAP net income for the fourth quarter was $124.7 million, or $1.24 per diluted share, and for fiscal 2022 was $343.2 million, or $3.47 per diluted share. The results and guidance are furnished under Item 2.02 and are not deemed filed for purposes of Section 18 of the Exchange Act.

Feb 6, 2023
8-K
Material Agreements

Neurocrine Biosciences 8-K Report, Material Agreement (Jan 9, 2023)

On January 8, 2023, Neurocrine Biosciences, Inc. entered into a Collaboration and License Agreement with Voyager Therapeutics, Inc. covering gene therapy products for the GBA1 gene, targeting Parkinson's disease and other GBA1-associated diseases, plus three new programs directed to rare central nervous system (CNS) genetic targets. The collaboration takes effect upon expiration or termination of Hart-Scott-Rodino waiting periods and receipt of any required approvals (Antitrust Clearance). Neurocrine will pay Voyager an upfront cash payment of approximately $136.0 million and, under a stock purchase agreement, buy 4,395,588 Voyager common shares at $8.88 per share for approximately $39.0 million. Voyager's upfront consideration totals $175 million including the equity purchase, and the agreement provides for aggregate development milestones of up to $985.0 million for the GBA1 Program and up to $175.0 million for each of the three New Discovery Programs, plus commercial milestones and tiered royalties on net sales. Voyager holds an option to co-develop and co-commercialize GBA1 Program products in the U.S. after receiving topline data from the first Phase 1 trial. If exercised, the companies would share U.S. costs, profits and losses equally. Neurocrine would otherwise be responsible for funding development through the first Phase 1 trial and, under the press release, for the full cost of the three new programs. The agreement also amends and restates the parties' investor agreement, providing for standstill, lock-up and voting arrangements, and Neurocrine's Chief Scientific Officer, Jude Onyia, Ph.D., is to join Voyager's board of directors. The Company may terminate the agreement on 180 days' or one year's notice depending on whether the notice precedes or follows first commercial sale, and may terminate for clinical trial failures or certain safety findings. Voyager may terminate if the equity purchase is not completed or if the Company challenges Voyager's patents. The filing also notes that the full agreements will be filed as exhibits to the Company's Form 10-K for fiscal 2022.

Jan 9, 2023
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Nov 1, 2022)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported third-quarter 2022 results in a press release furnished as Exhibit 99.1 to this Form 8-K. Third-quarter product sales, net were $379.3 million and total revenues were $387.9 million, compared with $288.8 million and $296.0 million in the third quarter of 2021. INGREZZA (valbenazine) net product sales were $376 million, with total prescriptions of approximately 68,600. The filing states that INGREZZA net product sales and TRx grew 31% and 32%, respectively, versus the third quarter of 2021, and that sequential growth was driven by record new patients and continued strength in existing patients' refill rates. GAAP net income was $68.5 million, or $0.69 per diluted share, versus $22.5 million, or $0.23 per diluted share, a year earlier. Non-GAAP net income was $106.7 million, or $1.08 per diluted share. The company raised its 2022 INGREZZA net product sales guidance to $1.400 billion to $1.425 billion. It reaffirmed 2022 operating expense guidance, with GAAP R&D of $415 million to $450 million, non-GAAP R&D of $360 million to $395 million, GAAP SG&A of $720 million to $735 million, and non-GAAP SG&A of $605 million to $620 million. The company also said it expects to begin making cash payments for federal income tax in the fourth quarter of 2022, based on available federal net operating losses and tax credits. Total cash, cash equivalents and marketable securities were $1,162.0 million at September 30, 2022. The filing also reports the all-cash acquisition of Diurnal Group plc on November 1, 2022, for an aggregate value of approximately GBP 48.3 million, or approximately $56 million, and the submission of a supplemental New Drug Application for valbenazine in chorea associated with Huntington disease. Pipeline milestones cited include top-line Phase 2 data for NBI-827104 in the fourth quarter of 2022, and registrational data for crinecerfont in congenital adrenal hyperplasia and Phase 2 data for NBI-921352 in focal onset seizures in 2023.

Nov 1, 2022
8-K
Regulation FD

Neurocrine Biosciences 8-K Report, Regulation FD Disclosure (Aug 30, 2022)

On August 30, 2022, Neurocrine Biosciences, Inc. announced, under Rule 2.7 of the U.K. City Code on Takeovers and Mergers, that it had reached agreement with Diurnal Group plc ("Diurnal") on the terms of a recommended all-cash acquisition. Under the agreement, the Company would acquire the entire issued and to be issued ordinary share capital of Diurnal (other than shares owned by the Company or held in treasury) for an aggregate value of approximately £48,300,000 (approximately $56.5 million USD). The transaction is conditional on, among other things, approval by Diurnal shareholders. The Company believes the deal provides an opportunity to accelerate the establishment of its clinical development and commercial capabilities in the United Kingdom, to the benefit of patient communities and other stakeholders. The filing is furnished under Item 7.01 (Regulation FD Disclosure) and states that it is not deemed "filed" for Section 18 purposes. It also includes forward-looking statements, flagging risks including failure to satisfy closing conditions and failure of Diurnal shareholders to approve the transaction.

Aug 30, 2022
8-K
Earnings & ResultsExhibits & Filings

Neurocrine Biosciences 8-K Report, Financial Results (Aug 4, 2022)

Neurocrine Biosciences, Inc. reported financial results for the second quarter ended June 30, 2022, and raised its 2022 INGREZZA net product sales guidance to $1.35 billion to $1.40 billion. Second-quarter product sales were $352.0 million (Exhibit 99.1 cites INGREZZA net product sales of $350 million), and total revenues were $378.2 million, compared with $288.9 million in the year-ago quarter. The company reported a GAAP net loss of $16.9 million, or $0.18 per diluted share, versus GAAP net income of $42.3 million, or $0.43 per diluted share, in the second quarter of 2021. The loss was primarily driven by a $70.0 million loss on extinguishment of convertible senior notes. Non-GAAP net income was $82.1 million, or $0.84 per diluted share. The company repurchased approximately 55% of its total debt outstanding in the quarter for an aggregate price of $279 million in cash, reducing total debt outstanding to $170 million. Cash, cash equivalents and marketable securities were approximately $1.1 billion at June 30, 2022. Updated 2022 guidance includes GAAP R&D expense of $415 million to $450 million and GAAP SG&A expense of $720 million to $735 million. The company also expects to begin making cash payments for federal income tax beginning in the fourth quarter of 2022. Pipeline news was mixed. The Phase 2a study of NBI-827104 in essential tremor did not meet specified endpoints, and the company does not plan to further develop that candidate in essential tremor. The FDA accepted the IND for NBI-1117568 for schizophrenia, with a Phase 2 study expected to start in the second half of 2022, which triggered a $30.0 million milestone payable to Sosei Heptares.

Aug 4, 2022
8-K
Other Events

Neurocrine Biosciences 8-K Report, Corporate Update (Jun 1, 2022)

Neurocrine Biosciences, Inc. disclosed in a Form 8-K filed June 1, 2022 that on May 31, 2022 it entered into separate, privately negotiated transactions with certain holders of its 2.25% Convertible Senior Notes due 2024 (the "2024 Notes") to repurchase approximately $31.4 million aggregate principal amount of those notes. The aggregate repurchase price is approximately $41.5 million, including accrued and unpaid interest. The repurchases are expected to close on June 2, 2022, subject to customary closing conditions. The filing states that these repurchases are in addition to the 2024 Notes repurchases the company previously disclosed in an 8-K filed May 25, 2022. The company also notes that repurchases of the 2024 Notes could affect the market price of its common stock. The filing is brief and reports no other financial results, operating developments, or guidance. Its forward-looking statements cover the amount and timing of the repurchases and their impact on the stock price, and cite risks including common stock price changes and conditions in the convertible note and capital markets.

Jun 1, 2022
8-K
Other EventsExhibits & Filings

Neurocrine Biosciences 8-K Report, Corporate Update (May 25, 2022)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) disclosed in this Form 8-K, filed May 25, 2022, that on May 24, 2022 it entered into separate, privately negotiated transactions with certain holders of its 2.25% Convertible Senior Notes due 2024 (the "2024 Notes") to repurchase approximately $179.4 million aggregate principal amount. The aggregate repurchase price is an estimated cash amount equal to the sum of approximately $224.0 million, an amount based in part on the trading price of the Company's common stock, and accrued and unpaid interest. The repurchases are expected to close over a period ending June 14, 2022, subject to customary closing conditions. According to the attached press release (Exhibit 99.1), approximately $201.8 million of 2024 Notes will remain outstanding following the repurchases, down from an initial principal balance of $517.5 million. CFO Matt Abernethy stated that the company has reduced its convertible debt levels by approximately 60% over the past two years to minimize shareholder dilution, and that capital allocation priorities remain focused on growing INGREZZA and advancing mid-to-late-stage clinical programs. The Company cautioned that the repurchases could affect the market price of its common stock, and it identified changes in its stock price and in the convertible note and capital markets as factors that could cause actual results to differ materially.

May 25, 2022
8-K
Leadership ChangesShareholder Matters

Neurocrine Biosciences 8-K Report, Executive Changes (May 23, 2022)

Neurocrine Biosciences, Inc. filed this Form 8-K to report results from its 2022 Annual Meeting of Stockholders, held May 18, 2022. Of 95,509,161 shares of common stock entitled to vote as of the March 21, 2022 record date, 86,613,599 shares were present in person or by proxy. Stockholders voted on five matters, and all proposals were approved or ratified. Stockholders approved an amended and restated 2020 Equity Incentive Plan and an amended and restated 2018 Employee Stock Purchase Plan. The filing states that a summary of the material terms of both plans appears in the definitive proxy statement filed April 7, 2022, which is incorporated by reference. The advisory vote on named executive officer compensation passed with 92.76% of votes cast in favor. The vote to approve the amended 2020 Plan passed with 89.01% in favor, and the ESPP amendment passed with 99.56% in favor. The three Class II directors, Richard F. Pops, Shalini Sharp and Stephen A. Sherwin, M.D., were elected to terms expiring at the 2025 Annual Meeting. Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 93.28% of votes cast in favor. The Class III directors (Kevin C. Gorman, Ph.D., Gary A. Lyons and Johanna Mercier) and Class I directors (William H. Rastetter, Ph.D., George J. Morrow and Leslie V. Norwalk) continue in office.

May 23, 2022
Page 1 of 6